Successfull form submission tick

Thanks for your details!

One of our legal specialists will review your details and call you back within 24 hours to discuss this further.

Alternatively to speak to a specialist
for FREE call us now on 0800 888 6888

Successfull form submission tick

Thanks for your feedback!

We take all of our feedback seriously so we can learn what we're doing right, wrong and how we can improve.

If you would like to speak to us regarding your feedback please email us at compliance@hampsonhughes.com

Pancreatic cancer – test gives hope

Scientists have developed a urine test that could help to detect a protein ‘signature’ linked to pancreatic cancer.

The study was published by Clinical Cancer Research (CCR), a journal of the American Association for Cancer Research. CCR’s focus is primarily to publish pioneering clinical and translational cancer research studies that bridge the laboratory and the clinic. According to an article on the BBC’s website, cancer charities have hailed the ‘much needed’ study.

Pancreatic cancer in the UK

Almost 9000 people are diagnosed with pancreatic cancer in the UK each year. Over 80% of pancreatic cancer patients are not eligible for surgery to remove the tumour – currently the only prospective cure available. This is due to diagnosis often occurring once the disease has already spread. Pancreatic cancer has the lowest survival rate (of the common cancers). Just three percent of patients survive for five years following diagnosis.

Heavy smokers, obese people, newly diagnosed diabetics over 50, and those with a family history of cancer are at a higher risk of developing the disease.

Pancreatic cancer – study and results

The Spanish and UK scientists who developed the test looked at nearly 500 urine samples. Almost 200 of which were from pancreatic cancer sufferers, 80 from healthy individuals, and 92 from patients with chronic pancreatic diseases. The remaining samples were made up of those with cancerous and benign conditions affecting the gall bladder or liver.

The level of three particular proteins was much higher in the urine of those with pancreatic cancer. This protein signature can help to determine whether the most common form of the disease is present. The article states that so far, the signature has proved to be 90% accurate.

Professor Nick Lemoine, of the Barts Cancer Institute, who co-authored the study, said:

“It’s really exciting because for the first time we might be able to
bring forward the window of opportunity for patients with
pancreatic cancer – from something that is advanced
and late stage to something that is early stage
and potentially curable by surgery.
“Patients are usually diagnosed when the cancer is already at a terminal
stage, but if diagnosed at stage 2, the survival rate is 20%, and
at stage 1, the survival rate for patients with very
small tumours can increase up to 60%.”

Fiona Osgun, Cancer Research UK, stated:

“At the moment, we’re a long way from knowing if this research could
lead to a test that would help detect pancreatic cancer at
an early stage, or who that test might benefit.

“But research like this is vital as there’s been little progress
in improving survival for pancreatic cancer, and
innovative approaches are needed.”

Scientists will now focus future research on individuals at greater genetic risk of pancreatic cancer.

BBC
Clinical Cancer Research

Free Advice

We offer a free legal consultation
to every potential client

No Win No Fee

Many of our claims are offered on
No Win No Fee payment terms

Use our App

Our Free App allows you to
manage your compensation claim

9/10

of our clients were
completely satisfied

9/10

of our clients would
use us again

9/10

of our clients would
recommend our services

65M

in compensation
won for our clients

Screenshot of the Claim Test used to check if you have a claim

Find out how much you can claim with our compensation calculator

It's really quick and easy, find out in 30 seconds.

See what you're owed!
Call us FREE on
0800 888 6888
or request a call back